EA201791970A1 - Способ лечения первичного склерозирующего холангита - Google Patents

Способ лечения первичного склерозирующего холангита

Info

Publication number
EA201791970A1
EA201791970A1 EA201791970A EA201791970A EA201791970A1 EA 201791970 A1 EA201791970 A1 EA 201791970A1 EA 201791970 A EA201791970 A EA 201791970A EA 201791970 A EA201791970 A EA 201791970A EA 201791970 A1 EA201791970 A1 EA 201791970A1
Authority
EA
Eurasian Patent Office
Prior art keywords
holangitis
sclerosed
treating primary
subject
treating
Prior art date
Application number
EA201791970A
Other languages
English (en)
Inventor
Брихад Абхианкар
Original Assignee
Милленниум Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Милленниум Фармасьютикалз, Инк. filed Critical Милленниум Фармасьютикалз, Инк.
Publication of EA201791970A1 publication Critical patent/EA201791970A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Описан способ лечения субъекта с первичным склерозирующим холангитом, включающий введение указанному субъекту эффективного количества гуманизированного антитела или его антиген-связывающего фрагмента, обладающего специфичностью связывания по отношению к α4β7-интегрину.
EA201791970A 2015-03-06 2016-03-04 Способ лечения первичного склерозирующего холангита EA201791970A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562129698P 2015-03-06 2015-03-06
PCT/US2016/020819 WO2016144720A1 (en) 2015-03-06 2016-03-04 Method of treating primary sclerosing cholangitis

Publications (1)

Publication Number Publication Date
EA201791970A1 true EA201791970A1 (ru) 2018-07-31

Family

ID=55699788

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791970A EA201791970A1 (ru) 2015-03-06 2016-03-04 Способ лечения первичного склерозирующего холангита

Country Status (11)

Country Link
US (2) US20180051086A1 (ru)
EP (2) EP4257200A3 (ru)
JP (1) JP6942053B2 (ru)
KR (1) KR20170120622A (ru)
AU (1) AU2016229193A1 (ru)
BR (1) BR112017019071A2 (ru)
CA (1) CA2978725A1 (ru)
EA (1) EA201791970A1 (ru)
MA (1) MA41636A (ru)
MX (1) MX2017011272A (ru)
WO (1) WO2016144720A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017234010A1 (en) * 2016-03-14 2018-09-27 Millennium Pharmaceuticals, Inc. Methods of treating or preventing graft versus host disease
CA3017743A1 (en) * 2016-03-14 2017-09-21 Millennium Pharmaceuticals, Inc. Method of preventing graft versus host disease
US11389533B2 (en) 2016-06-12 2022-07-19 Takeda Pharmaceutical Company Limited Method of treating inflammatory bowel disease
JP2022529929A (ja) * 2019-04-17 2022-06-27 ミレニアム ファーマシューティカルズ， インコーポレイテッド α４β７阻害薬及びＩＬ－２３阻害薬の併用療法
WO2020252069A1 (en) * 2019-06-10 2020-12-17 Millennium Pharmaceuticals, Inc. METHODS OF PRODUCING AN ANTI-α4β7 ANTIBODY

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
CA2212702C (en) 1995-02-10 2010-04-20 Leukosite, Inc. Mucosal vascular addressins and uses thereof
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
ES2321994T3 (es) * 1998-05-13 2009-06-15 Genentech, Inc. Diagnostico y tratamiento de trastornos hepaticos.
US7238717B2 (en) 2002-05-24 2007-07-03 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
EP1798223B2 (en) 2002-11-18 2014-07-30 ChemoCentryx, Inc. Aryl sulfonamides
ZA200701575B (en) 2004-09-03 2008-09-25 Genentech Inc Humanized anti-betA7 antagonists and uses therefor
EP1948691A1 (en) * 2005-11-17 2008-07-30 Millennium Pharmaceuticals, Inc. HUMANIZED IMMUNOGLOBULIN REACTIVE WITH a4ß7INTEGRIN
MA33213B1 (fr) 2009-03-20 2012-04-02 Amgen Inc Anticorps antagoniste specifique d'un heterodimere alpha-4-beta-7
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
WO2012151247A2 (en) 2011-05-02 2012-11-08 Millennium Pharmaceuticals, Inc. FORMULATION FOR ANTI-α4β7 ANTIBODY

Also Published As

Publication number Publication date
EP4257200A2 (en) 2023-10-11
WO2016144720A1 (en) 2016-09-15
AU2016229193A1 (en) 2017-09-21
JP2018508526A (ja) 2018-03-29
EP3265492A1 (en) 2018-01-10
MX2017011272A (es) 2018-01-12
US20180051086A1 (en) 2018-02-22
KR20170120622A (ko) 2017-10-31
US20210388092A1 (en) 2021-12-16
MA41636A (fr) 2018-01-09
EP4257200A3 (en) 2024-01-03
CA2978725A1 (en) 2016-09-15
JP6942053B2 (ja) 2021-09-29
BR112017019071A2 (pt) 2018-04-17

Similar Documents

Publication Publication Date Title
EA201890162A1 (ru) Антитела к cd40 с повышенной агонистической активностью
ECSP17008984A (es) Tratamientos conjuntos con anticuerpos anti cd40
CL2022001189A1 (es) Anticuerpos para cd40. (divisional de solicitud n° 2017003427)
EA201892480A1 (ru) Соединения, модулирующие fxr (nr1h4)
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
MX370818B (es) Anticuerpos anti-b7-h1 para tratar tumores.
EA201892482A1 (ru) Соединения, модулирующие fxr (nr1h4)
EA201792413A1 (ru) Антитела против cd71, активируемые антитела против cd71 и способы их применения
EA201792414A1 (ru) Антитела против cd166, активируемые антитела против cd166 и способы их применения
EA201791970A1 (ru) Способ лечения первичного склерозирующего холангита
EA201792589A1 (ru) Антитела против cd123 и конъюгаты указанных антител
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
EA201691974A1 (ru) Антитела против ox40 и способы их применения
BR112018012929A2 (pt) anticorpos anti-cd20/anti-cd3 biespecíficos para tratar leucemia linfoblástica aguda
EA201791208A1 (ru) Антитела к cd38 для лечения острого миелолейкоза
EA201890093A1 (ru) Комбинированная терапия гемобластозов антителами к cd38 и ингибиторами сурвивина
BR112016019871A2 (pt) anticorpos anti-cd38 para o tratamento de leucemia linfoblástica aguda
MX359794B (es) Anticuerpos anti-hepcidina y usos de los mismos.
EA201891925A1 (ru) Антитела к cd40 с усиленной агонистической активностью
BR112016027881A2 (pt) antagonistas de pdl-1 e pd-1 para o tratamento de cânceres negativos para o hpv
BR112017002433A2 (pt) anticorpos anticeramida
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
EA201992318A1 (ru) Композиции и способы для диагностики и лечения рака предстательной железы с использованием молекулы, связывающей прогастрин
BR112016008082A2 (pt) métodos para tratamento de doença pulmonar obstrutiva crônica usando benralizumab
EA201690446A1 (ru) Лечение множественной миеломы